Zobrazeno 1 - 10
of 726
pro vyhledávání: '"Filgotinib"'
Autor:
Peter C. Taylor, Bryan Downie, Ling Han, Rachael Hawtin, Angie Hertz, Robert J. Moots, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1383-1392 (2024)
Abstract Introduction High baseline neutrophil-to-lymphocyte ratio (NLR) in rheumatoid arthritis (RA) has been associated with positive responses to biologic tumor necrosis factor inhibition and negative responses to conventional synthetic disease-mo
Externí odkaz:
https://doaj.org/article/8791698927c94580b5379123fd399380
Autor:
Atsuhiko Sunaga, Takuya Inoue
Publikováno v:
Respirology Case Reports, Vol 12, Iss 9, Pp n/a-n/a (2024)
Abstract Filgotinib, a janus kinase 1 (JAK1) inhibitor, is used in the treatment of rheumatoid arthritis (RA). RA‐associated interstitial lung disease (RA‐ILD) is a severe RA complication with no established effective treatment. We report the cas
Externí odkaz:
https://doaj.org/article/4eba297bb63c4a40a09582cf4a8d6046
Autor:
Shahed Kamal, Sheng Wei Lo, Samantha McCall, Beverly Rodrigues, Andrew H. Tsoi, Jonathan P. Segal
Publikováno v:
Biologics, Vol 4, Iss 2, Pp 177-186 (2024)
Background: Janus kinase (JAK) inhibitors represent a novel class of oral therapies showing efficacy in treating ulcerative colitis (UC) and Crohn’s disease (CD), challenging conventional treatment paradigms. Summary: This review provides an overvi
Externí odkaz:
https://doaj.org/article/1716a5aa3a404f73bc4f5652574fdebb
Autor:
Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard G. Combe, Daniel Aletaha, Toshihiko Kaise, Vijay Rajendran
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1399-1415 (2023)
Abstract Filgotinib is an oral preferential Janus kinase 1 inhibitor that demonstrated significant reductions in radiographic progression, with an acceptable tolerability and safety profile, vs placebo in patients with rheumatoid arthritis (RA) and a
Externí odkaz:
https://doaj.org/article/9d82d21b56b644fa97f3e0c2369b2bb0
Autor:
Alejandro Balsa, Siegfried Wassenberg, Yoshiya Tanaka, Anne Tournadre, Hans-Dieter Orzechowski, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, James Galloway, Patrick Verschueren
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1555-1574 (2023)
Abstract Introduction This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA and the impact of BMI on the efficacy and safety of
Externí odkaz:
https://doaj.org/article/cb7d913272d643b0add44635e413c404
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hiroshi Nakase
Publikováno v:
Immunological Medicine, Vol 46, Iss 3, Pp 121-130 (2023)
AbstractRecent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowe
Externí odkaz:
https://doaj.org/article/5d6f6417665f433da8e4cff988bec47a
Autor:
Toshimasa Shimizu, Shin-ya Kawashiri, Shimpei Morimoto, Yurika Kawazoe, Shohei Kuroda, Rina Kawasaki, Yasuko Ito, Rieko Kiya, Shuntaro Sato, Hiroshi Yamamoto, Atsushi Kawakami
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background Administration of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs has dramatically improved even the clinical outcomes in patients with rheumatoid arthritis (RA) and an inadequate response to met
Externí odkaz:
https://doaj.org/article/25a2e315a7824154b75a46afcd9aa87a
Autor:
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe
Publikováno v:
Intestinal Research, Vol 21, Iss 1, Pp 110-125 (2023)
Background/Aims The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods SELECTION (NCT02914522) was a
Externí odkaz:
https://doaj.org/article/d7f57edfaba24c2f9b5b590bd3380150
Autor:
Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 161-185 (2022)
Abstract Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by estimated radiographic progression rate before baseline (BL) in patients with rheumatoid arthritis (RA) who had inadequate response to methotrex
Externí odkaz:
https://doaj.org/article/5ad3c011326f47e39cc3a991b6b2f59f